Equity Overview
Price & Market Data
Price: $0.011
Daily Change: -$0.009 / 81.82%
Daily Range: $0.011 - $0.02
Market Cap: $29,800,200
Daily Volume: 50,732
Performance Metrics
1 Week: -31.25%
1 Month: -35.29%
3 Months: -44.72%
6 Months: -43.15%
1 Year: 1,275%
YTD: -55.82%
Details
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.